THE CHALLENGE
Advanced cancer patients with non-small cell lung cancer and melanoma were facing grim prognoses, but Seagen had developed SEA-CD40 – a breakthrough immunotherapy that could potentially turn their own immune systems into powerful cancer-fighting weapons. The challenge was enormous: recruit patients across seven countries and ten languages for a complex five-cohort study, each testing different combinations of this revolutionary treatment. With patients’ lives hanging in the balance and limited time to prove this therapy’s effectiveness, every enrollment mattered, but international clinical trials often fail due to recruitment barriers and cultural misunderstandings.
THE SOLUTION
We created a global recruitment ecosystem that made Seagen’s groundbreaking immunotherapy accessible to cancer patients who had run out of conventional options. Instead of overwhelming desperate patients with complex study protocols, we crafted culturally sensitive materials that spoke directly to their hope for more time with loved ones and their desire to help others facing the same battle. Our multilingual approach ensured that language barriers didn’t prevent patients from accessing potentially life-saving treatment, while clear cohort explanations helped them understand which path offered the best chance for their specific cancer type. The result: a recruitment strategy that not only achieved enrollment targets but also established a new model for inclusive global cancer research that truly serves patients regardless of geography or language.
